Zembrace Symtouch

  • Migraine and headache

Zembrace Symtouch Generic Name & Formulations

General Description

Sumatriptan (as succinate) 3mg/0.5mL; soln for SC inj.

Pharmacological Class

Selective 5-HT1B/1D receptor agonist.

How Supplied

Single-dose prefilled autoinjector—4


Generic Availability


Mechanism of Action

Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Zembrace Symtouch Indications


Acute treatment of migraine with or without aura.

Limitations of Use

Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.

Zembrace Symtouch Dosage and Administration


≥18yrs: 3mg by SC inj. Reevaluate if no response. Max cumulative dose: 12mg in 24hrs with each dose separated by at least 1hr. May also be given at least 1hr following another sumatriptan product.


<18yrs: not recommended.

Zembrace Symtouch Contraindications


Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor. Severe hepatic impairment.

Zembrace Symtouch Boxed Warnings

Not Applicable

Zembrace Symtouch Warnings/Precautions


Avoid excessive use. Exclude underlying neurologic or cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur or if serotonin syndrome is suspected. Peripheral or GI vascular ischemia and infarction following other 5-HT1 agonists. History, or risk of seizures. Elderly. Pregnancy. Nursing mothers (avoid nursing for 12 hours after treatment).

Zembrace Symtouch Pharmacokinetics




Renal. Half-life: 115 ± 19 minutes.

Zembrace Symtouch Interactions


See Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.

Zembrace Symtouch Adverse Reactions

Adverse Reactions

Inj site reactions, tingling, dizziness/vertigo, warm/hot/burning sensation, feeling of heaviness/tightness, pressure sensation, flushing, numbness/paresthesia; medication overuse headache; rare: serious cardiac and cerebrovascular events (including fatalities), vision loss, hypertensive crisis, hypersensitivity reactions.

Zembrace Symtouch Clinical Trials

See Literature

Zembrace Symtouch Note

Not Applicable

Zembrace Symtouch Patient Counseling

See Literature